| pubmed-article:2871137 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2871137 | lifeskim:mentions | umls-concept:C0678133 | lld:lifeskim |
| pubmed-article:2871137 | lifeskim:mentions | umls-concept:C0205267 | lld:lifeskim |
| pubmed-article:2871137 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:2871137 | lifeskim:mentions | umls-concept:C0086960 | lld:lifeskim |
| pubmed-article:2871137 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:2871137 | pubmed:dateCreated | 1986-6-6 | lld:pubmed |
| pubmed-article:2871137 | pubmed:abstractText | Taxol is a plant product derived from the western yew, Taxus brevifolia. We have conducted a phase I clinical study of Taxol used intravenously daily for 5 days at 3-week intervals. The starting dose was 5 mg/m2 daily, and the highest dose used was 40 mg/m2 daily for 5 days. The daily dosage of Taxol was mixed in 250 mL of intravenous fluid and infused over a period of 1 hour. A total of 20 patients with metastatic solid tumors refractory to standard therapy received 45 courses of therapy. Taxol was generally well tolerated and caused no significant nausea or vomiting. A mild degree of diarrhea was reported by six patients, and a moderate degree of stomatitis at the higher dose levels developed in four patients. All patients treated in the dosage range of 20 mg/m2 to 40 mg/m2 experienced nearly complete alopecia. Myelosuppression, predominantly in the form of leukopenia, was the dose-limiting toxicity. The nadir of leukopenia was reached between days 8 and 12 followed by complete recovery between days 15 and 21. Leukopenia was first observed following the Taxol dosage level of 20 mg/m2/d, was moderately severe at the dosage level of 30 mg/m2/d, and was severe at the dosage level of 40 mg/m2/d. No objective tumor regression was observed. A starting dosage level of 30 mg/m2/d for 5 days is recommended for phase II trials using this schedule. | lld:pubmed |
| pubmed-article:2871137 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2871137 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2871137 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2871137 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2871137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2871137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2871137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2871137 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2871137 | pubmed:month | May | lld:pubmed |
| pubmed-article:2871137 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:2871137 | pubmed:author | pubmed-author:LeghaS SSS | lld:pubmed |
| pubmed-article:2871137 | pubmed:author | pubmed-author:TenneyD MDM | lld:pubmed |
| pubmed-article:2871137 | pubmed:author | pubmed-author:KrakoffI RIR | lld:pubmed |
| pubmed-article:2871137 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2871137 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:2871137 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2871137 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2871137 | pubmed:pagination | 762-6 | lld:pubmed |
| pubmed-article:2871137 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:meshHeading | pubmed-meshheading:2871137-... | lld:pubmed |
| pubmed-article:2871137 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:2871137 | pubmed:articleTitle | Phase I study of taxol using a 5-day intermittent schedule. | lld:pubmed |
| pubmed-article:2871137 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2871137 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2871137 | lld:pubmed |
